92 results about "CD34" patented technology

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

The invention provides an RNP compound, an electrotransfection composition and a pharmaceutical composition thereof, a CD34 + cell gene editing method using the composition, and a method for obtaining HBG gene target mutation in a CD34 + cell genome.

A reagent kit, staining method, and application for combining dual immunohistochemistry with elastin fiber staining. The reagent kit includes a combination of primary antibodies, consisting of anti-CK7 and anti-CD34 monoclonal antibodies from different species, such as rabbit anti-human CK7 monoclonal antibody and mouse anti-human CD34 monoclonal antibody. By selecting CK7 and CD34 as the primary antibody combination, the growth pattern of tumor epithelium can be accurately indicated, and the proliferation and thickening of alveolar septal fibrous tissue caused by tumors can be clearly revealed, as opposed to structural changes of alveoli induced by other factors. Combined with independent Victoria blue staining, the elastin fibers of the walls of arteries and veins, as well as the pleura of the lungs, can be clearly visualized, aiding in the assessment of the integrity of elastin fibers on the lung surface and in determining the extent of tumor infiltration.

Provided are a method for inducing differentiation of pluripotent stem cells into CD34+ hematopoietic stem / progenitor cells and a culture medium composition thereof. Provided are a method for inducing differentiation of pluripotent stem cells into CD34+ hematopoietic stem / progenitor cells or NK cells and a culture medium composition thereof. The NK cells obtained using the provided culture method have high purity and good in vitro expansion effect; the yield of iNK cells is high, and a single iPSC can differentiate into approximately 2,000 NK cells; and the obtained iNK cells highly express CD16 (over 70%). As a result, the problem of low CD16 expression in iNK cells in the prior art, which requires genetic modification methods to solve, has been addressed.

The present invention relates to a method for treating aging, and in particular immunosenescence, restoring thymic function and regenerating the thymus in a subject in need thereof, comprising the administration of T cell progenitors comprising CD7+CD34- cells.

The invention relates to an immune Raman multicolor imaging kit for liver cancer prediction and evaluation, the immune Raman multicolor imaging kit comprises five Raman probes, and the Raman probes are composed of Raman balls and antibodies connected to the surfaces of the Raman balls; wherein the Raman sphere is formed by polymerizing a triple bond monomer and (i) acrylic acid or (ii) styrene and acrylic acid, the particle size is 10-100 nm, and the Raman shift is 1800-2800 cm <-1 >; antibodies of the five Raman probes are respectively selected from one of an AFP antibody, an HBX antibody, a GPC3 antibody, a GS antibody and a CD34 antibody. The immune Raman multicolor imaging reagent and kit provided by the invention can realize one-step marking and multiple color development of five liver cancer related protein markers in the same liver tissue slice. Compared with a multiple fluorescence immunohistochemical technology, the method has remarkable advantages in efficiency and precision. Experiments show that the detection result is consistent with the clinical diagnosis result, and the application potential is huge.

The integration procedure provides different elements that require in vitro amplification of HSPCs, preferably for about 48 hours, in the presence of hematopoietic cytokines as well as UM171 and stem cell regenerative factor 1, and the introduction of i) a system (e.g., a CRISPR / Cas9 system) that generates DNA double-strand breaks (DSBs) upstream of the transcription start site of the target gene, and ii) the introduction of a donor matrix comprising cDNA with homologous arms on both sides (left [LHA] and right [RHA]).

Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.

The invention discloses a method for constructing astrocytes serving as a smoke disease model, and belongs to the technical field of crossing of stem cells and neuroscience. The method comprises the following steps: S1) reprogramming CD34 + cells in in-vitro PBMCs (peripheral blood mononuclear cells) of smoke disease patients carrying and not carrying RNF213p.R4810K mutation to obtain induced pluripotent stem cells; and S2) directionally inducing and differentiating the induced pluripotent stem cells into astrocytes through a neural progenitor cell way, wherein the obtained astrocytes are the astrocytes capable of being used as the smoke disease model. The astrocyte model prepared by the invention can be used for researching pathogenesis, nerve-blood vessel interaction process and blood-brain barrier (BBB) related functions of smoke diseases, and can be further applied to molecular typing of diseases and in-vitro function evaluation of candidate drugs.

The present disclosure relates to methods, media and supplements for culturing target cells, such as hematopoietic stem and progenitor cells (HSPC). The methods, media, and supplements of the present disclosure may include one or more epigenetic modifiers within culture conditions to culture and / or expand target cells, such as HSPC or CD34 + cells, such as may be obtained, enriched, or isolated from infected / diseased or normal primary samples. Output populations of HSPCs amplified in the presence of one or more epigenetic modifiers may be suitable for use in downstream applications.

Multispecific molecules that include an anti-G6B antibody or binding fragment thereof, an anti- CD34 antibody or binding fragment thereof; and one, two or all of: an immune cell engager (e.g., selected from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, and a macrophage cell engager); a cytokine molecule; a modulator of a cytokine molecule; a stromal modifying moiety; or any combination thereof are disclosed. Additionally disclosed are nucleic acids encoding the same, and methods of treating conditions or diseases using the aforementioned molecules.

The invention provides a biomarker for detecting anti-VEGF treatment typing of diabetic macular edema and extracellular vesicle protein for judging the severity of diabetic retinopathy, and the protein with remarkable expression difference is screened out by analyzing the expression difference of the extracellular vesicle protein in aqueous humor of a patient. Wherein C5 and CD34 can be used as biomarkers of DME anti-VEGF treatment typing, C5 can be used for judging the severity of diabetic retinopathy (DR), important guidance is provided for DME or DR personalized treatment, and the C5 and CD34 have wide clinical application prospects.

The present invention provides methods for engrafting a bone marrow organoid with CD34+ hematopoietic stem and progenitor cells. Compositions comprising the factors needed for engraftment are also provided.

Compositions and methods are provided for modifying eukaryotic cells, e.g., to express a transgene of interest and / or to generate a population of expanded cells ex vivo.SOLUTION: A method of transducing a population of eukaryotic cells, such as a population of pluripotent cells, to express a gene of interest by contacting the cells with a viral vector, e.g., a lentiviral vector, and a diblock copolymer, e.g., a diblock copolymer comprised of a hydrophilic region and a hydrophobic region. For example, the diblock copolymer can be composed of polyoxyethylene (PEO) subunits and polyoxypropylene (PRO) subunits. In addition, the compositions and methods of the invention can be used to promote the ex vivo expansion or survival of a population of pluripotent cells (e.g., CD34 + hematopoietic stem or progenitor cells), for example, by contacting the cells with a diblock copolymer.SELECTED DRAWING: None

The invention provides a method of producing a population of CD34+ hematopoietic precursor cells. The CD34+ hematopoietic precursor cells are used in methods of producing natural killer (NK), methods of inducing NK cell differentiation from pluripotent stem cells (PSCs), and methods of generating terminally differentiated hematopoietic cells from PSCs. The differentiation of immune cells such as NK cells from PSCs includes the use of a hemogenic endothelium induction cocktail that includes a WNT signaling pathway activator, a bone morphogenetic protein and / or a vascular endothelial growth factor. Also provided is a method of producing hematopoietic stem cells from pluripotent stem cells.

According to the isolated culture identification and key marker detection method for the down producing goat hair follicle stem cells, trypsin and EDTA are used for jointly digesting skin tissue, and high-activity cells are efficiently obtained; a culture medium containing various growth factors is adopted for culture, and cell proliferation and stemness maintenance are promoted. And identifying and integrating morphological observation, growth curve determination and clone formation experiment to accurately judge the characteristics of the cells. Immunofluorescent staining and real-time fluorescent quantitative PCR are applied to key marker detection, and expression of markers such as CK15, CD34 and beta1 integrin is detected with high sensitivity. The method is high in separation efficiency, accurate in identification and sensitive in marker detection, can provide sufficient high-quality cells for the research on the hair follicle stem cells of the cashmere goat, assists in deeply understanding the biological characteristics and the regulation mechanism of the cells, and is of great significance for improving the yield and quality of cashmere and promoting the development of related biotechnologies.

The invention provides a smoke disease model and a construction method and application thereof, and belongs to the technical field of smoke disease model construction. The method for constructing the smog disease model comprises the following steps: extracting CD34 + hematopoietic progenitor cells in peripheral blood of a smog disease patient, reprogramming to generate hiPSC, further differentiating into brain organs and vascular organs, fusing the brain organs and the vascular organs, and culturing and constructing the vascularized brain organ smog disease model. The smoke disease model constructed by adopting the construction method disclosed by the invention can simulate and reproduce phenotypes such as tiny branch increase, macrovascularization, pericytopenia, smooth muscle fibrosis deposition, abnormal angiogenesis increase and the like in clinical core pathological phenotypes of smoke disease patients, and is superior to existing animal and cell models to a certain extent.

Provided are an induced NK cell, and a preparation method therefor and the use thereof. The method comprises mixing a CD34+ cell with a stromal cell, co-culturing the mixture to obtain an NK precursor cell, and subjecting the NK precursor cell to induction and amplification culture to obtain a mature NK cell, wherein the stromal cell comprises any one or a combination of at least two of an AFT024 cell, an MS5 cell, an OP9 cell, an HS-5 cell, an MSC cell, an MUTZ-3 cell, a stromal cell derived from tissues such as bone marrow or the liver, or a primary cell. Provided is the development of a brand-new method for inducing an NK cell on the basis of a CD34+ cell, which enables the induction of the NK cell with a high efficiency. The efficiency of outputting NK cells from a single CD34+ cell is improved, and the property of the induced NK cell is very close to that of a natural mature NK cell. They have uniform anti-tumor effects, can effectively kill tumor cells, and have broad application prospects.

The present disclosure provides methods related to tissue regeneration using human mesenchymal stem cell (MSC) / CD34+ hematopoietic stem / progenitor cell (HSPC) co-cultured total conditioned media. In particular, the present disclosure provides novel methods for treating and / or preventing damage to, trauma to, and / or loss of tissue.

本发明公开了一种CD34+造血干细胞化学重编程为诱导多能干细胞的方法。所述方法包括：将CD34+造血干细胞分散为单细胞，接种于包被细胞外基质的培养表面，在无血清培养基中依次进行三阶段诱导培养：第一阶段培养基包含丙戊酸、CHIR99021、RepSox、EPZ6438、PY60、OAC1和OAC2；第二阶段培养基包含丙戊酸、CHIR99021、RepSox、反苯环丙胺、TTNPB、Forskolin、OAC1和OAC2；第三阶段培养基包含CHIR99021、Forskolin、Y‑27632、SP600125、OAC1和OAC2。最后挑取形成的iPSC克隆进行扩增培养，获得诱导多能干细胞。本发明针对CD34+造血干细胞优化了小分子组合和诱导时序，全程无病毒、无转录因子、无血清，重编程效率可达3%以上，细胞凋亡率低，可获得具有完整多能性和正常核型的iPSC，适用于临床级细胞制备和再生医学应用。

The invention relates to the technical field of biological medicine and tissue engineering, in particular to a tissue engineering blood vessel and a preparation method and application thereof. The tissue engineering blood vessel is obtained by modifying interleukin 24 (IL-24) on the surface of an acellular blood vessel, after the tissue engineering blood vessel is transplanted into a body, the number of CD31 + and CD34 + cells can be remarkably increased, and infiltration of M2 type macrophages (CD163 +) on the surface of the blood vessel is remarkably increased; the expression of HIF-1 alpha (hypoxia marker) and MMP9 is obviously reduced; the expression of the nerve specific protein S-100 is obviously increased, thrombosis and intimal hyperplasia are effectively inhibited, and the patency rate of transplanted blood vessels is obviously increased.

The invention discloses a method for inducing pluripotent stem cells into myeloid progenitor cells and a culture medium used by the method. According to the method, firstly, a method for inducing pluripotent stem cells into hematopoietic stem / progenitor cells is optimized, the hematopoietic stem / progenitor cells with the CD34 + cell proportion accounting for 92.63% are obtained, then three different schemes are adopted for conducting induction culture on the obtained hematopoietic stem / progenitor cells, and finally it is found that the induction amplification effect of the induction culture method in the third scheme is the best; the induced amplification efficiency of the myeloid progenitor cells is effectively improved. According to the myeloid progenitor cell induction culture medium provided by the invention, the induction amplification efficiency of the myeloid progenitor cells is improved, and the differentiation proportion of hematopoietic stem / progenitor cells to the myeloid progenitor cells (Lin-CD34 + CD38 +) is greatly improved. The invention is of great significance to preparation and application of myeloid progenitor cells.

This invention relates to an immunoRaman multicolor imaging kit for the prediction and assessment of liver cancer. The immunoRaman multicolor imaging reagent contains five Raman probes, which are composed of Raman spheres and antibodies attached to the surface of the Raman spheres. The Raman spheres are polymerized from triple-bonded monomers with (i) acrylic acid or (ii) styrene and acrylic acid, with a particle size of 10–100 nm and a Raman shift of 1800–2800 cm⁻¹. ‑1 The antibodies used for the five Raman probes are selected from one of the following: AFP antibody, HBX antibody, GPC3 antibody, GS antibody, and CD34 antibody. The immunoRaman multicolor imaging reagent and kit provided by this invention can achieve one-step labeling and multiplex color development of five liver cancer-related protein markers in the same liver tissue section. Compared with multiplex fluorescence immunohistochemistry, this invention has significant advantages in both efficiency and accuracy. Experiments show that the detection results of this invention are consistent with clinical diagnostic results, demonstrating great application potential.

This invention discloses a quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34 and its preparation method, relating to the field of flow cytometry quality control technology. The preparation method of this invention successfully prepared a quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34. The quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34 provided by this invention, as the first domestic quality control sample for CD34 flow cytometry counting, fills a gap in this product field in China. This quality control sample has performance close to imported reagents, uses the same operating method, and does not incur additional learning costs; furthermore, the product's shelf life can be stably maintained at 45–50 days, and its usage cost is far lower than imported quality control samples.

In order to identify NK progenitor cells and provide a method for producing mature NK cells or CAR-NK cells using said progenitor cells, it was found that CD56−CD34− cells are NK progenitor cells that are major sources in the production of CAR-NK cells.

Described herein are compositions and methods for modifying eukaryotic cells, for example, to express a transgene of interest and / or to produce an expanded population of cells ex vivo. Using the compositions and methods of the disclosure, a population of eukaryotic cells, such as a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) may be transduced to express a gene of interest by contacting the cells with a viral vector, such as a lentiviral vector, and a poloxamer. Additionally, the compositions and methods described herein can be used to promote the proliferation or survival of a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) ex vivo, for example, by contacting the cells with a poloxamer. Examples of poloxamers that may be used in conjunction with the compositions and methods of the disclosure are those having a molar mass in excess of 10,000 g / mol, as well as those having a molar mass of polyoxypropylene subunits greater than 2,000 g / mol and / or an ethylene oxide content of greater than 40% by mass.

The invention relates to a method for preparing a therapeutic RNA platelet carrier. The method comprises at least the following steps: transducing at least one therapeutic RNA sequence together with at least one therapeutic RNA packaging sequence comprising an RNA binding protein sequence to a megakaryocyte progenitor cell and / or a hematopoietic stem and progenitor cell expressing CD34, using a DNA-based vehicle; the present invention relates to a therapeutic RNA sequence and / or packaging sequence encoding at least one therapeutic RNA product in a megakaryocyte (e.g., HSPC), an immature megakaryocyte, and / or a megakaryocyte; activating expression of the therapeutic RNA sequence and / or the therapeutic RNA packaging sequence; and generating platelets from a mature megakaryocyte derived from a transduced progenitor cell of the megakaryocyte and / or a transduced hematopoietic stem and progenitor cell (HSPC) expressing CD34 and / or a transduced immature megakaryocyte and / or a transduced megakaryocyte, wherein the expression activation step is regulated to occur during megakaryocyte maturation and / or platelet formation wherein the generated platelet carrier is functionally reactive to activation with a specific agonist wherein the generated platelet carrier is activated by an extracellular signal, and wherein the expression activation step is regulated to occur during megakaryocyte maturation and / or platelet formation. And wherein the platelet carrier produced contains the at least one therapeutic RNA product. The invention also relates to a therapeutic RNA platelet carrier engineered by the above method and its therapeutic use. In addition, the present invention relates to a pharmaceutical composition comprising an RNA platelet carrier engineered by the above method and therapeutic uses thereof.

The present invention relates to a method for producing red blood cells, and more specifically, to (S1) culturing pluripotent stem cells to obtain a culture medium containing hematopoietic stem cells, and (S2) obtaining CD41 from the culture medium. - and CD34 - The present invention relates to a method for producing red blood cells of superior quality in a short period of time, comprising the steps of (S3) obtaining a cell population and (S3) maturing the obtained cell population in a first medium containing erythropoietin.

Methods to improve homing and engraftment of hematopoietic stem cells, particularly cord blood CD34+ cells, for use in hematopoietic cell transplantation through the regulation of expression of YTHDF2 or FTO in CD34+ cells. The methods include transiently repressing expression of YTHDF2 through exposure of the CD34+ cells to YTHDF2 repressor compound. The methods also include exposing CD34+ cells to a FTO expression activator compound to transiently increase FTO expression in the cells.